Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(14%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
3
43%
Ph phase_2
3
43%
Ph phase_3
1
14%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)
N/ANon-phased studies
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(2)
Terminated(1)
Other(2)

Detailed Status

unknown2
Completed2
Not yet recruiting1
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (42.9%)
Phase 31 (14.3%)
N/A3 (42.9%)

Trials by Status

not_yet_recruiting114%
unknown229%
withdrawn114%
completed229%
recruiting114%

Recent Activity

1 active trials
Showing 5 of 7
recruitingphase_2

Efficacy of L-menthol on Breathlessness in Interstitial Lung Disease

NCT07398287
not_yet_recruitingphase_2

Efficacy of L-menthol on Breathlessness in Asthma

NCT07500974
completedphase_2

Efficacy of L-menthol on Breathlessness in Chronic Obstructive Pulmonary Disease

NCT05888597
withdrawnnot_applicable

Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch

NCT03943407
completednot_applicable

Investigation of a New Human Model for Itch

NCT04711044
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07398287Phase 2

Efficacy of L-menthol on Breathlessness in Interstitial Lung Disease

Recruiting
NCT07500974Phase 2

Efficacy of L-menthol on Breathlessness in Asthma

Not Yet Recruiting
NCT05888597Phase 2

Efficacy of L-menthol on Breathlessness in Chronic Obstructive Pulmonary Disease

Completed
NCT03943407Not Applicable

Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch

Withdrawn
NCT04711044Not Applicable

Investigation of a New Human Model for Itch

Completed
NCT04593836Phase 3

Antiperistaltic Effect and Safety of L-menthol in the Elderly With Contraindication to Buscopan

Unknown
NCT03132142Not Applicable

Desensitization of Nociceptive Afferents by Application of Topical Capsaicin, Trans-cinnamaldehyde and L-menthol

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7